Reinnervate
and Mirus Bio announced a commercial agreement to launch a new range of
products for the transfection of cells cultured in 3D.
Under the
agreement, Mirus will produce and sell kits combining TransIT-3D Transfection
Reagent, alvetex 3D cell culture plates, and detailed protocols for achieving
transfection of selected cell lines growing in 3D.
The kits
will enable scientists to evaluate the growth of cells in 3D, allowing more
native cell structure, morphology, and functionality before transfection with a
specific gene of interest with a robust transfection protocol.
“Scientists
are increasingly looking for in-vitro
cell-based assays that better mimic and predict complex biological processes,”
comments Richard Rowling, commercial director at Reinnervate. “We believe the
3D Transfection System will be of broad appeal for cell biologists seeking to
improve their research capabilities beyond the limitations of mono-layer
culture. We are delighted to be collaborating with Mirus to help make 3D cell
culture a more routine laboratory technique.”
Reinnervate, www.reinnervate.com
